Published: 20 March 2026Pearce IP / BusinessToday / Health and Me / The Hindu BusinesslineHealth
Multiple Indian Pharma Companies Launch Generic Semaglutide on Day 1 of Novo Nordisk's Patent Expiry
AQuick answer
On March 21, 2026, multiple Indian pharma companies including Dr. Reddy's, Zydus, Alkem, NATCO, Sun Pharma, and Glenmark launched generic semaglutide (GLP-1 agonist) on Day 1 of Novo Nordisk's patent expiry, with prices as low as ₹1,290/month versus ₹8,000–₹15,000 for the branded version.
Key facts
On March 21, 2026 — Day 1 of Novo Nordisk's patent expiry — multiple Indian companies launched generic semaglutide: Dr. Reddy's, Zydus, Alkem, NATCO, Sun Pharma, and Glenmark.
Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist used to treat Type-2 diabetes and obesity; branded name Ozempic/Wegovy by Novo Nordisk.
Generic price: as low as ₹1,290/month versus ₹8,000–₹15,000/month for the branded version — a 6–12x cost reduction.
The patent cliff event demonstrates India's generic pharma strength and its ability to provide affordable healthcare solutions.
GLP-1 agonists are among the fastest-growing drug classes globally due to dual efficacy in blood sugar control and weight reduction.
This launch is significant for India's Pharma Vision 2047 goals and positions Indian companies in the global obesity drug market.
On March 21, 2026 — the day Novo Nordisk's core Indian patent for semaglutide (brand names: Ozempic® for diabetes, Wegovy® for obesity) expired — at least five major Indian pharmaceutical companies launched their own generic versions simultaneously. Dr. Reddy's launched Obeda™ at approximately ₹4,200 per month, Zydus Lifesciences released Semaglyn™, Mashema™, and Alterme™ at around ₹2,200 per month, and Alkem Laboratories introduced Semasize™, Obesema™, and Hepaglide™ starting at ₹1,800 per month. NATCO Pharma was among the first to market at ₹1,290, while Sun Pharma and Glenmark also entered the market.
Semaglutide is a GLP-1 receptor agonist used to manage Type 2 diabetes and obesity. Novo Nordisk's branded versions had been priced at ₹8,000–₹15,000 per month in India, making them unaffordable for most patients. The generic launch marks a watershed moment for access to diabetes and obesity care in India — a country with the world's second-largest diabetic population (over 100 million patients). For Rajasthan, where lifestyle diseases including diabetes are rising in urban centres like Jaipur and Jodhpur, affordable semaglutide could significantly improve public health outcomes.
0
Mains angle
Q: How does the Day 1 generic semaglutide launch by multiple Indian companies impact healthcare access and pharma competitiveness?
Answer (50 words):
On March 21, 2026, five major companies launched generic semaglutide as Novo Nordisk's patent expired. NATCO priced it at ₹1,290 monthly versus ₹8,000-15,000 for branded versions. India has over 100 million diabetes patients. The simultaneous launch demonstrates India's pharmaceutical strength and dramatically improves affordability of diabetes and obesity treatment.
Tap an option below. Correct or incorrect feedback appears instantly.
Linked questionMedium
On March 21, 2026, multiple Indian pharmaceutical companies launched generic versions of semaglutide. Which of the following statements about semaglutide is/are CORRECT?
1. Semaglutide is a GLP-1 receptor agonist used for Type 2 diabetes and obesity.
2. Novo Nordisk's core Indian patent for semaglutide expired on March 21, 2026.
3. NATCO Pharma was the only company to launch a generic version on Day 1.
Select the correct answer using the code below:
Explanation · Correct answer B
Statements 1 and 2 are correct. Semaglutide is indeed a GLP-1 receptor agonist approved for Type 2 diabetes (Ozempic®) and obesity (Wegovy®). Novo Nordisk's core Indian patent expired on March 21, 2026, triggering simultaneous generic launches. Statement 3 is INCORRECT — multiple companies launched generics on Day 1, including Dr. Reddy's (Obeda™), Zydus (Semaglyn™/Mashema™/Alterme™), Alkem (Semasize™/Obesema™/Hepaglide™), NATCO Pharma, Sun Pharma, and Glenmark. NATCO was among the first to announce pricing at ₹1,290/month but was not the only company.
What is semaglutide and why is it medically significant?
Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist used to treat Type-2 diabetes and obesity. It works by mimicking a gut hormone that stimulates insulin release and reduces appetite. Sold under the brand names Ozempic and Wegovy by Novo Nordisk, it has become one of the world's fastest-growing drug classes due to its dual efficacy in blood sugar control and weight reduction.
Which Indian pharma companies launched generic semaglutide and when?
Dr. Reddy's, Zydus, Alkem, NATCO, Sun Pharma, and Glenmark launched generic semaglutide on March 21, 2026 — the very first day of Novo Nordisk's patent expiry. This simultaneous Day-1 launch by multiple Indian companies demonstrated the country's competitive generic manufacturing capabilities.
How much cheaper is generic semaglutide compared to the branded version?
Generic semaglutide launched at prices as low as ₹1,290 per month, compared to ₹8,000–₹15,000 per month for Novo Nordisk's branded versions (Ozempic/Wegovy). This represents a cost reduction of 6 to 12 times, dramatically improving affordability for Indian patients managing Type-2 diabetes and obesity.
What does the term 'patent cliff' mean and how does it relate to this event?
A 'patent cliff' refers to the expiry of a patent that protected a drug from generic competition, after which generic manufacturers can legally produce and sell the same molecule. March 21, 2026 marked the patent cliff for semaglutide in India, triggering immediate Day-1 launches from six Indian companies and sharply reducing prices.
How does the generic semaglutide launch relate to India's Pharma Vision 2047?
Pharma Vision 2047 aims to make India the global leader in affordable, high-quality generic medicines by India's centenary of independence. The rapid, coordinated Day-1 launch of generic semaglutide — one of the world's most sought-after drugs — positions Indian pharma companies as key players in the global obesity and diabetes drug market and reinforces India's identity as 'pharmacy of the world'.
Was this useful?
Share corrections or missing exam angles with the editorial team.
